Aim: This study evaluated the efficacy and safety of vaginal progesterone gel that was administered daily for luteal phase support as part of in vitro fertilization/embryo transfer (IVF/ET) cycles in Japanese women. 
Progesterone for luteal phase support is typically given from the day of oocyte retrieval up to weeks 7-10 of pregnancy and may be administered orally, vaginally (as a tablet, capsule, or gel), or intramuscularly. Each route of administration has different characteristics in terms of pharmacokinetics and potency, as well as adverse event (AE) profiles. [2] [3] [4] As such, it is important that an effective and well-tolerated form is used to ensure both optimal outcomes and patient well-being.
Oral progesterone requires the administration of high doses to reach appropriate serum concentrations, which can result in a number of side-effects, including sedation, drowsiness, and nausea. 5, 6 Vaginal administration of progesterone delivers high local concentrations to the vagina and uterus with low peripheral serum concentrations, reducing the risk for systemic side-effects that can be observed with oral or intramuscular administration. 3 There is, however, the inconvenience of vaginal discharge, and possibly irritation, following this route of administration. Intramuscular progesterone is typically prepared in oil, is rapidly absorbed following injection, and maintains a steady state for ≤72 hours. [5] [6] [7] There is the possibility of injection site reactions, including pain, inflammation, and abscesses, with this route of administration, as well as rare complications, including a severe allergic reaction. [5] [6] [7] Outside of Japan, vaginally administered progesterone is widely used as luteal phase support for IVF/embryo transfer (ET) cycles, whereas in Japan, until recently, there was no approved vaginal progesterone preparation for luteal phase support. Injected progesterone or in-house formulations of progesterone were therefore used. Since 2014, a vaginal tablet containing 100 mg of progesterone has been available in Japan for luteal phase support during assisted reproductive technology (ART) cycles. 8 Previous studies, outside of Japan, that compared vaginal progesterone gel and vaginal progesterone tablets indicated that there were no substantial differences in outcomes with either formulation.
Patient ease-of-use, satisfaction, and convenience were greater with the gel, compared with the tablets, resulting in a better overall impression of the gel formulation, compared with the tablets. [9] [10] [11] [12] [13] Here, the results of a phase III trial that was conducted to evaluate the efficacy and safety of 8% vaginal progesterone gel that was 
| Study participants

| Study treatments and interventions
Vaginal progesterone gel (COL-1620 8%; Crinone ® 8%, Merck KGaA, 
| Study objectives and endpoints
The primary objective of the trial was to demonstrate the non- 
| Statistical analysis
Based on the reference clinical pregnancy rate per ET of 24.3% (JSOG 2009 registry) 14 and a 10% non-inferiority margin, overall, 117 participants were planned to be enrolled to demonstrate that the lower limit (historical standard value) was above −10% in both analysis sets then non-inferiority was assumed.
The secondary efficacy analysis of the biochemical pregnancy rate per ET was calculated as a percentage, with 95% CI values calculated using an exact (Clopper-Pearson) method. Safety was assessed in the safety population, which included all the participants who received at least one dose of the vaginal progesterone gel.
| RESULTS
A total of 195 women were screened for inclusion in this trial and 178 were enrolled and entered the screening period (Fig. 2) . Of these women, 169 started controlled ovarian stimulation and 162 received an hCG injection to trigger ovulation, with all the women who discontinued before the hCG injection doing so because of risk of OHSS.
Following the hCG injection, 149 women received at least one dose of the vaginal progesterone gel, representing the safety population, and 123 women underwent IVF/ET, representing the ITT population.
The PP population included 115 participants and, in total, 121 women completed the trial. Overall, the most frequent reasons for discontinuation were risk of OHSS (n=17), AEs (n=17), and the participant not undergoing IVF/ET (n=14).
| Baseline characteristics and demographics
In the ITT population, the mean (standard deviation [SD]) age of the women who received the vaginal progesterone gel was 34.5 Table 1 ). The majority of the women F I G U R E 1 Trial design. β-hCG, β-human chorionic gonadotropin; COS, controlled ovarian stimulation; Max., maximum had primary infertility (69.1%), with 46.3% of the women having female-only infertility and 44.7% having unexplained infertility. The most common cause of female infertility was a tubal factor. The data were similar for the PP population ( Table 1 ). The baseline demographics and patient characteristics were not available for the historical control data.
| Efficacy evaluation
In the ITT population, the clinical pregnancy rate per ET (95% CI) was 28.5% (20.7%-37.3%), compared with 24.3% in the historical control population ( Table 2 ). 14 The lower bound of the 95% CI minus 24.3%
for the prospective arm (−3.6%) was above the predefined −10%
limit for non-inferiority to the historical control. In the PP population the clinical pregnancy rate per ET was 27.8% (19.9%-37.0%) and the lower bound of the 95% CI was also above the predefined −10% limit for non-inferiority to the historical control ( Table 2 ). The biochemical pregnancy rate per ET (95% CI) was 7.3% (3.4%-13.4%) in the ITT population and 7.8% (3.6%-14.3%) in the PP population.
| Safety evaluation
The safety profile of the vaginal progesterone gel was as expected during this 12 week trial (Table 3 ). In the safety population, the most frequently reported TEAE was OHSS, which was reported by 32 (21.5%) participants, with mild, moderate, and severe OHSS reported by 24 (16.1%), four (2.7%), and four (2.7%) participants, respectively. None of the cases of OHSS reported was assessed as being related to the study drug.
TEAEs related to the vaginal progesterone gel were reported by 15 
| DISCUSSION
This open-label, single-arm trial of vaginal progesterone gel demonstrated that the clinical pregnancy rate per ET was non-inferior to that observed in the historical registry data in Japan (28.5% vs 24.3%, respectively). Furthermore, a clinical pregnancy rate of 22.7% was observed in more recent (2013) Japanese registry data. 16 The higher clinical pregnancy rate that was observed in this study, compared with the registry data, is probably related to the younger mean age of the women who were enrolled in the study, compared with the registry associated with the historical data. Nonetheless, the clinical pregnancy rate that was observed in the present trial was similar to that observed in a clinical trial in Japan of a 100 mg vaginal progesterone tablet (22.2%), 17 as well as to that of a trial comparing an oral progestogen (chlormadinone acetate) and intramuscular progesterone for luteal phase support in Japan (20% and 25%, respectively). 18 Moreover, these data are in line with the results of a meta-analysis by Polyzos et al, 11 which demonstrated that there is no difference in clinical pregnancy rates following luteal phase support with vaginal progesterone gel compared with all other vaginal progesterone forms. The observed clinical pregnancy rate in the current study is also comparable with that observed in European studies of vaginal progesterone gel in women undergoing IVF/intracytoplasmic sperm injection cycles with oocyte retrieval (32.3%-32.9%). 9, 19 The biochemical pregnancy rate in the present trial (7.3%) was low and similar to that reported for the trial comparing an oral progestogen and intramuscular progesterone for luteal phase support in Japan (5% and 10%, respectively). 18 The safety profile of the vaginal progesterone gel was as expected during the trial, with no new safety issues identified. The most frequently reported TEAE was OHSS, with mild-to-severe OHSS reported by 21.5%
of the safety population. None of the cases of OHSS were assessed as being related to the study drug by the investigator. This rate is similar to that observed in a trial of a vaginal progesterone tablet containing 100 mg of progesterone that was given either twice or three-times daily, during which OHSS was observed in 20.4% of the participants. 17 Furthermore, the incidence of moderate-to-severe OHSS (5.4%) was within the range that is typically observed during IVF cycles (3.1%-8.0%). 20 In addition, it should be noted that the underlying etiology of OHSS is gonadotropin rather than progesterone exposure, suggesting that its occurrence was not related to the vaginal progesterone gel. 21 Previous studies, outside of Japan, comparing vaginal progesterone gel and vaginal progesterone tablets have indicated that, owing to the treatment regimen (once daily with vaginal gel, compared with twice or three-times daily with a vaginal tablet), the gel is considered to be more convenient to use. The potential limitations of this study include its open-label nature and the fact that it compared outcomes against historical data, which might not reflect any recent changes in clinical care. However, it should be noted that the clinical pregnancy rate per ET was similar in both the current trial and the historical data to that observed in a recent clinical trial of luteal phase support in Japan with vaginal progesterone tablets. 14, 17 This suggests that the historical data are still a valid comparator.
In At least one TEAE leading to trial termination 10 (6.7)
At least one TEAE related to the vaginal progesterone gel, leading to dose modification or discontinuation of the vaginal progesterone gel 11 (7.4) At least one TEAE leading to death 0 (0.0) TEAE, treatment emergent adverse event. for IVF/ET cycles in Japanese women, with the clinical pregnancy rate per ET observed to be non-inferior to the historical standard value from the JSOG registry. Furthermore, the vaginal progesterone gel demonstrated the expected safety profile, with no new clinical safety issues identified. The once-per-day application makes progesterone gel a highly convenient option for luteal phase support in women undergoing ART.
